MedTrace Logo

ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT)

NCT01748253 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-05-21

No results posted yet for this study

Summary

Evaluation of 24-hour antihypertensive effect of long-acting ARB-CCB tablet administrated to hypertensive patients with atrial fibrillation, and comparison of 24-hour antihypertensive effect of long-acting ARB-CCB tablet between morning administration and bedtime administration.

Conditions

  • Hypertension and Atrial Fibrillation

Interventions

DRUG

Telmisartan-amlodipine tablet administration group (morning)

Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks

DRUG

Telmisartan-amlodipine tablet administration group (bedtime)

Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks

Sponsors & Collaborators

  • Acrobat Trial Group

    lead NETWORK

Principal Investigators

  • Kazuomi Kario · Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-10-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01748253 on ClinicalTrials.gov